UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000015634
Receipt number R000018170
Scientific Title Phase I study of EBV specific CTL generated from third party for treatment of EBV associated lymphoproliferative disorder after allogeneic stem cell transplantation
Date of disclosure of the study information 2014/11/07
Last modified on 2023/11/14 12:44:56

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Phase I study of EBV specific CTL generated from third party for treatment of EBV associated lymphoproliferative disorder after allogeneic stem cell transplantation

Acronym

EBV specific CTL for treatment of EBV associated LPD after stem cell transplant

Scientific Title

Phase I study of EBV specific CTL generated from third party for treatment of EBV associated lymphoproliferative disorder after allogeneic stem cell transplantation

Scientific Title:Acronym

EBV specific CTL for treatment of EBV associated LPD after stem cell transplant

Region

Japan


Condition

Condition

EBV associated lymphoproliferative disorder after allogeneic stem cell transplantation

Classification by specialty

Hematology and clinical oncology Pediatrics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the safety of EBV specific CTL generated from third party for the treatment of EBV associated lymphoproliferative disorder after allogeneic stem cell transplantation

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase

Phase I


Assessment

Primary outcomes

Incidence of adverse events and graft-versus-host disease

Key secondary outcomes

Monitoring of EBV viral load and EBV specific CTL in peripheral blood
Clinical course of EBV infection


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Maneuver

Interventions/Control_1

Administration of EBV specific CTL induced and expanded from donor peripheral blood of third party

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Prior allogeneic hematopoietic stem cell transplantation
2. HLA-A0201/0206, HLA-A2402 or HLA-1101
3. Rituximab resistant, difficulty in administering rituximab or CD20 negative EBV associated lymphoproliferative disorder
4. Written informed consent from patient or legal representative
5. Fulfill all of the following criteria:
Performance status 0-3, GOT /GPT =<10 x upper normal limit (UNL), total bilirubin =<3 x UNL,
serum creatinine =<3 x UNL, SpO2>=90% (room air)

Key exclusion criteria

1. Severe or uncontrollable bacterial, fungal,and viral (except EBV) infection
2. Uncontrollable GVHD
3. Uncontrollable heart failure
4. Psychoses
5.History of allergic reaction to albumin

Target sample size

9


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yoshiyuki Takahashi

Organization

Nagoya University Graduate School of Medicine

Division name

Department of Pediatrics

Zip code


Address

65 Tsurumai-cho, Showa-ku, Nagoya, Aichi

TEL

052-744-2942

Email

ytakaha@med.nagoya-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Nobuhiro Nishio

Organization

Nagoya University Hospital

Division name

Center for Advanced Medicine and Clinical Research

Zip code


Address

65 Tsurumai-cho, Showa-ku, Nagoya, Aichi

TEL

052-744-2942

Homepage URL


Email

nnishio@med.nagoya-u.ac.jp


Sponsor or person

Institute

Nagoya University Graduate School of Medicine,
Department of Pediatrics

Institute

Department

Personal name



Funding Source

Organization

Nagoya University Hospital

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

名古屋大学医学部附属病院(愛知県)


Other administrative information

Date of disclosure of the study information

2014 Year 11 Month 07 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2014 Year 10 Month 10 Day

Date of IRB

2016 Year 01 Month 05 Day

Anticipated trial start date

2014 Year 11 Month 10 Day

Last follow-up date

2026 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2014 Year 11 Month 07 Day

Last modified on

2023 Year 11 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018170


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name